KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Free Cash Flow: 2015-2025

Historic Free Cash Flow for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $354.5 million.

  • BeOne Medicines' Free Cash Flow rose 547.86% to $354.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $544.6 million, marking a year-over-year increase of 154.76%. This contributed to the annual value of -$633.3 million for FY2024, which is 63.17% up from last year.
  • Latest data reveals that BeOne Medicines reported Free Cash Flow of $354.5 million as of Q3 2025, which was up 58.69% from $223.4 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Free Cash Flow registered a high of $354.5 million during Q3 2025, and its lowest value of -$689.4 million during Q1 2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$205.5 million (2024), whereas its average is -$162.8 million.
  • As far as peak fluctuations go, BeOne Medicines' Free Cash Flow plummeted by 3,728.74% in 2022, and later surged by 547.86% in 2025.
  • Over the past 5 years, BeOne Medicines' Free Cash Flow (Quarterly) stood at $12.1 million in 2021, then plummeted by 3,728.74% to -$439.5 million in 2022, then increased by 13.87% to -$378.6 million in 2023, then soared by 95.43% to -$17.3 million in 2024, then spiked by 547.86% to $354.5 million in 2025.
  • Its Free Cash Flow stands at $354.5 million for Q3 2025, versus $223.4 million for Q2 2025 and -$15.9 million for Q1 2025.